Xiaoping Zheng

发表

Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.

J. Fargnoli, J. Barrish, J. Tokarski, 2005, Journal of medicinal chemistry.

Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)

J. Fargnoli, G. Derbin, J. Barrish, 2008, Journal of medicinal chemistry.

Crystal structure of GDC-0927 bound to estrogen receptor alpha

Siew K. Yeap, N. C. Ray, Jun Liang, 2019 .

Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.

Jun Liang, Y. Ran, L. Friedman, 2020, ACS medicinal chemistry letters.

Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template.

J. Fargnoli, J. Hunt, B. Fink, 2004, Journal of medicinal chemistry.

A Novel Application of a Pd(0)-Catalyzed Nucleophilic Substitution Reaction to the Regio- and Stereoselective Synthesis of Lactam Analogues of the Epothilone Natural Products

Soong-Hoon Kim, C. Fairchild, R. Borzilleri, 2000 .

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

J. Fargnoli, G. Derbin, J. Barrish, 2006, Journal of medicinal chemistry.

Zeolitic imidazolate framework-8 as a luminescent material for the sensing of metal ions and small molecules

D. Cao, Zhonghua Xiang, Zan Hu, 2011 .

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.

Siew K. Yeap, N. C. Ray, Jun Liang, 2021, Journal of medicinal chemistry.

From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.

Jun Liang, P. Trojer, Y. Ran, 2017, Bioorganic & medicinal chemistry letters.

Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.

Jun Liang, P. Trojer, R. Cummings, 2016, Bioorganic & medicinal chemistry letters.

Synthesis and bioactivity of novel (Z,E)-1-(substituted phenyl)-3-[α-(alkyloxyimino)benzylidene]pyrrolidine-2,4-dione derivatives

Chunlong Yang, Shengsheng Qiang, Xiaoping Zheng, 2011 .

Synthesis, characterization, and biological activities of novel (Z)-3-((E)-1-(alkyloxyimino)ethyl)-5-arylidene-4-hydroxypyrroline-2-one derivatives

Chunlong Yang, Shengsheng Qiang, Xiaoping Zheng, 2010 .

Discovery of GNE-502 as an Orally Bioavailable and Potent Degrader for Estrogen Receptor Positive Breast Cancer.

Jun Liang, Y. Ran, L. Friedman, 2021, Bioorganic & medicinal chemistry letters.

Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.

Jun Liang, J. Nwachukwu, K. Nettles, 2019, Bioorganic & medicinal chemistry letters.

Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.

J. Fargnoli, G. Derbin, J. Barrish, 2006, Journal of medicinal chemistry.

Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927.

Siew K. Yeap, N. C. Ray, Jun Liang, 2019, Bioorganic & medicinal chemistry letters.